title: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
abstract: OBJECTIVE
  A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule.
  
  
  METHODS
  Patients with stage IIIB-IV non-small-cell lung cancer (NSCLC) were randomly assigned to docetaxel 75 mg/m2 on day 1 every 3 weeks (3-weekly) and 35 mg/m2 on days 1, 8, and 15 (weekly) for < or = eight cycles. End points included survival (primary), toxicity, and response.
  
  
  RESULTS
  Of 215 patients enrolled, 208 (103 in the 3-weekly arm and 105 in the weekly arm) were assessable for response. At baseline, 24.5% of patients (51 out of 208) had received prior paclitaxel therapy and 43.3% of patients (90 out of 208) had been progression-free for more than 3 months after first-line therapy. After 12 months' follow-up, median survival was 6.3 months (95% CI, 4.68 to 7.84 months) with 3-weekly docetaxel and 9.2 months (95% CI, 5.83 to 12.59 months) with weekly docetaxel (P = .07) after a median of four (range, one to eight) and two (range, one to eight) treatment cycles, respectively. Overall, response rates were 12.6% v 10.5% with 3-weekly versus weekly docetaxel. Significantly fewer patients reported grade 3 to 4 toxicities with weekly docetaxel versus 3-weekly docetaxel (P < or = .05). There were significantly lower rates of grade 3 to 4 anemia (P < or = .05), leucopenia (P < .0001), and neutropenia (P < or = .001) with weekly versus 3-weekly treatment. No grade 3 to 4 thrombocytopenia or mucositis was reported.
  
  
  CONCLUSIONS
  Weekly docetaxel 35 mg/m2 demonstrated similar efficacy and better tolerability than standard 3-weekly docetaxel 75 mg/m2 and can be recommended as a feasible alternative second-line treatment option for patients with advanced NSCLC.
authors.affiliation: Martha-Maria City Hospital Halle-Doelau, Halle, Germany. wolfgang.schuette@medizin.uni-halle.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schuette
authors.forename: Sylke
authors.initials: S
authors.lastname: Nagel
authors.forename: Thomas
authors.initials: T
authors.lastname: Blankenburg
authors.forename: Christine
authors.initials: C
authors.lastname: Lautenschlaeger
authors.forename: Klaus
authors.initials: K
authors.lastname: Hans
authors.forename: Ernst-Wilhelm
authors.initials: EW
authors.lastname: Schmidt
authors.forename: Ina
authors.initials: I
authors.lastname: Dittrich
authors.forename: Hans
authors.initials: H
authors.lastname: Schweisfurth
authors.forename: Ludwig Fischer
authors.initials: LF
authors.lastname: von Weikersthal
authors.forename: Aruna
authors.initials: A
authors.lastname: Raghavachar
authors.forename: Angelika
authors.initials: A
authors.lastname: Reissig
authors.forename: Monika
authors.initials: M
authors.lastname: Serke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel